HGH Research Guide: Human Growth Hormone and the Somatotropic Axis

Human Growth Hormone (HGH), also known as Somatotropin, is a 191-amino acid single-chain polypeptide hormone secreted by somatotroph cells in the anterior pituitary gland. Recombinant HGH (rHGH) produced via recombinant DNA technology in E. coli or mammalian expression systems is structurally identical to pituitary-derived HGH and has been the subject of extensive pharmacological research since its introduction in the mid-1980s.

Endogenous GH secretion follows a pulsatile pattern regulated by two hypothalamic neuropeptides: Growth Hormone-Releasing Hormone (GHRH), which stimulates GH release, and Somatostatin, which inhibits it. GH secretion peaks during slow-wave sleep and is also stimulated by exercise, fasting, and hypoglycaemia. For laboratory research use only — not approved for therapeutic use outside of specific clinical indications in licensed medical settings.

RetaLABS stocks research-grade HGH 100IU (10 × 10IU vials), COA-backed and shipped Express Post to researchers across Australia.

GH exerts its effects through two primary mechanisms: direct receptor-mediated actions on target tissues, and indirect effects via Insulin-like Growth Factor 1 (IGF-1) produced primarily in the liver in response to GH stimulation.

The GH receptor (GHR) is a cytokine receptor superfamily member that signals via JAK2/STAT5 phosphorylation upon GH binding. Direct GH effects include lipolysis in adipose tissue, protein synthesis in muscle, and gluconeogenesis in the liver. IGF-1 signals through the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor activating PI3K/Akt and MAPK/ERK pathways — promoting cell proliferation, differentiation, and survival across multiple tissue types.

The GH/IGF-1 axis exhibits negative feedback: IGF-1 suppresses both hypothalamic GHRH secretion and pituitary GH secretion, establishing a regulated homeostatic loop. Research measuring IGF-1 levels as a surrogate biomarker for GH axis activity is common in both preclinical and clinical study designs.

Body composition is the most extensively studied endpoint in GH research. Controlled studies in GH-deficient adults and in age-related GH decline models have consistently demonstrated:

• Lean mass increases — GH treatment produces measurable increases in fat-free mass via protein anabolic effects mediated through GH receptor and IGF-1R signalling in skeletal muscle
• Fat mass reduction — GH's lipolytic effects on adipose tissue, particularly visceral adipose, are documented across multiple study populations; the DGHD (Adult GH Deficiency) literature provides the most rigorous controlled data
• Bone mineral density — GH/IGF-1 axis activation increases osteoblast activity; longitudinal studies in GH-deficient adults show significant BMD improvements with treatment

It is important to note that body composition effects in GH-sufficient individuals differ substantially from those observed in GH deficiency states — a distinction relevant to research design and interpretation.

Adult Growth Hormone Deficiency (AGHD) is the best-characterised clinical model for GH research. It arises from pituitary pathology, hypothalamic damage, or as a consequence of treatment for pituitary tumours, and produces a metabolic phenotype including increased visceral adiposity, reduced muscle mass, dyslipidaemia, and reduced bone density.

The NICE guidance and international consensus statements provide established diagnostic and treatment parameters for AGHD that serve as useful reference frameworks for researchers designing GH intervention studies. Paediatric GH deficiency models (linear growth failure) represent a distinct research area with different endpoint considerations — height velocity, bone age advancement, and final adult height prediction.

Beyond body composition, GH/IGF-1 axis research has examined cardiovascular risk profiles in GH deficiency. AGHD is associated with increased cardiovascular morbidity; GH replacement in deficient populations has been shown to improve lipid profiles (reduced LDL, increased HDL), endothelial function markers, and intima-media thickness in controlled studies.

Metabolic research has also examined GH's diabetogenic potential — GH antagonises insulin action, and supraphysiological GH exposure increases insulin resistance and glucose output. This effect is relevant to research protocol design, particularly in metabolic disease models where glucose homeostasis is a primary endpoint.

RetaLABS HGH 100IU is in stock and ships Express Post Australia-wide within 1–2 business days of confirmed payment. Supplied as 10 × 10IU lyophilised vials with a manufacturer COA documenting identity and purity. Payment via Bitcoin, Litecoin, or Monero — discreet packaging as standard.

Reconstitution protocol:

• Use bacteriostatic water for multi-dose vials; sterile water for single-use only
• Inject water slowly along the vial wall — do not inject directly onto the powder
• Gently swirl until dissolved — do not shake or vortex; GH is sensitive to mechanical degradation
• Typical research concentration: 10IU per 1mL (approximately 3.3mg/mL)
• Store lyophilised vials at 2–8°C (refrigerator) — unlike most peptides, lyophilised HGH does not require −20°C storage
• Reconstituted solution: 2–8°C, use within 3 weeks
• Avoid temperature cycling and protect from light

See the Peptide Reconstitution & Storage Guide for general protocol notes. For laboratory research use only.